United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Health Equity
Our Collaborations
Contact Us
Newsroom
2024 ASCO® Annual Meeting
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra®
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Provider
Patient
Pipeline & Data
Breast Radiation Score
Next Generation Cologuard
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Cancerguard™
Our Expertise
Cancerguard™ Science
Multi-Cancer Early Detection Thought Leadership
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Environmental, Social, and Governance (ESG)
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts in:
Press Releases
August 22, 2018
Exact Sciences And Pfizer Enter Into U.S. Promotion Agreement For Cologuard®
August 15, 2018
University Research Park Breaks Ground on Corporate Headquarters Building for Exact Sciences
June 26, 2018
Nurse Practitioners are Critical Source of Colorectal Cancer Screening Information for Patients, Survey Shows
May 30, 2018
Exact Sciences Applauds American Cancer Society's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49
January 07, 2018
Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017
October 30, 2017
Cologuard® revenue increased 158 percent to $73 million during third quarter
July 25, 2017
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests
April 28, 2017
Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
April 04, 2017
CMS includes Cologuard in updated Medicare Advantage Star Ratings
February 21, 2017
Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase
February 02, 2017
CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings
January 08, 2017
Exact Sciences to report $99 million in revenues, 150 percent growth for 2016
1
2
3
4
5
6
7
8